Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs

Journal of Veterinary Internal Medicine

Volumn 24, Issue 3, 2010, Pages 597-605

  Helmond, S E ^a,c   Polzin, D J ^a   Armstrong, P J ^a   Finke, M ^a   Smith, S A ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c Animal Health Diagnostic Center   (United States)

Author keywords

Anti Xa; Survival; Thromboembolism; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL; RISK;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTICOAGULANTS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN; MALE; ODDS RATIO;

ANIMALIA; CANIS FAMILIARIS;

EID: 77954356805     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2010.0505.x     Document Type: Article

References (36)

1. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 1999, 35:384-391.
2. Carr A, Panciera D, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: A retrospective study of 72 dogs. J Vet Intern Med 2002, 16:504-509.
3. Piek C, Junius G, Dekker A. Idiopathic immune-mediated hemolytic anemia: Treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med 2008, 22:366-373.
4. Weinkle T, Center S, Randolph J. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc 2005, 226:1869-1880.
5. Scott-Moncrieff JC, Treadwell NG, McCullough SM. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2001, 37:220-227.
6. Breuhl E, Moore G, Brooks M. A prospective study of unfractionated heparin therapy in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2009, 45:125-133.
7. Weiss D, Brazzell J. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 2006, 20:682-686.
8. McManus P, Craig L. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc 2001, 218:1308-1313.
9. Johnson L, Lappin M, Baker D. Pulmonary thromboembolism in 29 dogs: 1985-1995. J Vet Intern Med 1999, 13:338-345.
10. Klein M, Dow S, Rosychuk R. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: Ten cases (1982-1987). J Am Vet Med Assoc 1989, 195:246-250.
11. Keyes ML, Rush JE, Knowles KE. Pulmonary thromboembolism in dogs. J Vet Emerg Crit Care 1993, 3:23-32.
12. Burgess K, Moore A, Rand W. Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med 2000, 14:456-462.
13. Mason N, Duval D, Shofer FS. Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune-mediated hemolytic anemia in dogs: A randomized controlled clinical trial. J Vet Intern Med 2003, 17:206-212.
14. Mischke R. Hemostatic disorders as a complication of autoimmune hemolytic anemia in dogs. Dtsch Tierarztl Wochenschr 1998, 105:13-16.
15. Hendrick A. Auto-immune haemolytic anaemia-a high-risk disorder for thromboembolism? Hematology 2003, 8:53-56.
16. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126:188S-203S.
17. Balch A, Mackin A. Canine immune-mediated hemolytic anemia: Treatment and prognosis. Compend Contin Educ Vet 2007, 29:230-238.
18. Thompson M, Scott-Moncrieff J, Brooks M. Effect of a single plasma transfusion on thromboembolism in 13 dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2004, 40:446-454.
19. Rozanski E, Hughes D, Scotti M. The effect of heparin and fresh frozen plasma on plasma antithrombin III activity, prothrombin time and activated partial thromboplastin time in critically Ill dogs. J Vet Emerg Crit Care 2001, 11:15-21.
20. Diquélou A, Barbaste C, Gabaig A. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs. Vet Clin Pathol 2005, 34:237-242.
21. Harnett BE, Kerl ME. Unfractionated and low-molecular weight heparin for hypercoagulability in dogs and cats. Vet Med 2007, 102:187-205.
22. Young E, Podor T, Venner T. Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 1997, 17:1568-1574.
23. Raschke R, Hirsh J, Guidry J. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003, 138:720-723.
24. Kelly J, Hunt B. Do anticoagulants improve survival in patients presenting with venous thromboembolism? J Intern Med 2003, 254:527-539.
25. Hull R, Pineo G. Prophylaxis of deep venous thrombosis and pulmonary embolism. Current recommendations. Med Clin North Am 1998, 82:477-493.
26. Mischke R, Jacobs C. The monitoring of heparin administration by screening tests in experimental dogs. Res Vet Sci 2001, 70:101-108.
27. Mischke R. Heparin in vitro sensitivity of the activated partial thromboplastin time in canine plasma depends on reagent. J Vet Diagn Invest 2003, 15:588-591.
28. Morris T, Marsh J, Konopka R. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism. Thromb Res 2000, 100:185-194.
29. Hirsh J, Raschke R, Warkentin T. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995, 108:258S-275S.
30. Brooks MB. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma. Vet Clin Pathol 2004, 33:208-214.
31. Tyrrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995, 16:198-204.
32. Mannari D, Liu C, Hughes D. The role of heparin in alleviating complement-mediated acute intravascular haemolysis. Acta Haematol 2008, 119:166-168.
33. Griebsch C, Arndt G, Raila J. C-reactive protein concentration in dogs with primary immune-mediated hemolytic anemia. Vet Clin Pathol 2009, 38:421-425.
34. Mitchell K, Kruth S, Wood R. Serum acute phase protein concentrations in dogs with autoimmune hemolytic anemia. J Vet Intern Med 2009, 23:585-591.
35. Mischke R, Schüttert C, Grebe S. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs. Am J Vet Res 2001, 62:1887-1891.
36. Hellebrekers L, Slappendel R, van den Brom W. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog. Am J Vet Res 1985, 46:1460-1462.